Please try another search
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Name | Age | Since | Title |
---|---|---|---|
Jonas Einarsson | 65 | 2011 | Independent Chairman |
Kari Gronas | 60 | 2019 | Independent Director |
Henrik Schussler | 61 | 2015 | Director |
Ketil Fjerdingen | - | 2012 | Deputy Board member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review